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Epidermolysis bullosa acquisita (EBA) is a chronic mucocutaneous autoimmune skin blistering disease. Several
lines of evidence underscore the contribution of autoantibodies against type VII collagen (COL7) to the
pathogenesis of EBA. Furthermore, EBA susceptibility is associated with the MHC haplotype in patients (HLA-
DR2) and in immunization-induced EBA in mice (H2s). The latter study indicated an additional contribution of
non-MHC genes to disease susceptibility. To identify non-MHC genes controlling EBA susceptibility, we
intercrossed EBA-susceptible MRL/MpJ with EBA-resistant NZM2410/J and BXD2/TyJ as well as Cast mice. Mice of
the fourth generation of this four-way autoimmune-prone advanced intercross line were immunized with a
fragment of murine COL7 to induce EBA. Anti-COL7 autoantibodies were detected in 84% of mice, whereas
deposition of complement at the dermal–epidermal junction (DEJ) was observed in 50% of the animals; 33% of
immunized mice presented with overt clinical EBA. Onset of clinical disease was associated with several
quantitative trait loci (QTLs) located on chromosomes 9, 12, 14, and 19, whereas maximum disease severity was
linked to QTLs on chromosomes 1, 15, and 19. This more detailed insight into the pathogenesis of EBA may
eventually lead to new treatment strategies for EBA and other autoantibody-mediated diseases.
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INTRODUCTION
Both genes and environment determine susceptibility to
complex diseases, such as autoimmune and chronic inflam-
matory disorders (Naldi et al., 2005; Han et al., 2009; Bang
et al., 2010; Franke et al., 2010). In contrast to most
autoimmune diseases (Fernando et al., 2008), little is known
about the genetic basis of autoimmune skin blistering
diseases (ASBD). ASBD are clinically characterized by
cutaneous or mucocutaneous blistering, directly or indirectly
caused by binding of autoantibodies to structural components
of the skin (Amagai, 2008; Borradori and Bernard, 2008).
Most studies on the genetic basis of ASBD in patients
focused on associations with the HLA region, but varied
considerably between different populations. This may be due
to a relatively small number of patients recruited for these
association studies. In more detail, pemphigus vulgaris, an
ASBD with Dsg 3 as the target antigen (Amagai et al., 1991),
was found to be associated with HLA-DRW4 in a Jewish
cohort, with HLA-DQw1 and -DQw3 polymorphisms in
Ashkenazi Jews, HLA-DRB1*04 and DRB1*1401 in Iranian
patients, HLA-DRB1*0402 haplotypes in Venezuelan
patients, HLA-DQB1*0503, -B*1507 or -DRB1*1405 in
Japanese patients, as well as HLA-B38 and HLA-Bw55 in
an American cohort (Park et al., 1979; Szafer et al., 1987;
Miyagawa et al., 1999, 2002; Lee et al., 2006; Saenz-Cantele
et al., 2007; Shams et al., 2009). For bullous pemphigoid
(BP), an ASBD with antibodies directed against hemidesmo-
somal proteins termed BP180 (type XVII collagen, COL17)
and BP230 (Stanley et al., 1981, 1988; Diaz et al., 1990),
major histocompatibility complex (MHC) association stu-
dies have also not been conclusive (Delgado et al., 1996;
Okazaki et al., 2000). In 29 patients with epidermolysis
bullosa acquisita (EBA) and 5 patients with bullous lupus
erythematodes, an association with HLA-DR2 has been
described (Gammon et al., 1988). In dermatitis herpeti-
formis, a disorder associated with gluten-sensitive entero-
pathy and IgA antibodies to epidermal and tissue
transglutaminase (Sardy et al., 2002), a strong association
with HLA-DQ2 and HLA-DQ8 has been reported (Spurkland
et al., 1997).
Regarding the contribution of non-MHC genes to the
susceptibility to ASBD, conflicting results on Fc gamma
receptor polymorphisms have been reported in patients with
BP (Weisenseel et al., 2007; Guilabert et al., 2010). In
addition, polymorphisms in the IL-1b gene have been
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reported in female patients with BP (Chang et al., 2006).
However, these studies included relatively low numbers of
patients.
Studies on genetic susceptibility using animal models for
ASBD are also rare, as most models employ the passive
transfer of autoantibodies into mice (Bieber et al., 2010). On
the basis of a strong association of dermatitis herpetiformis
with HLA-DQ2 and HLA-DQ8 (Spurkland et al., 1997),
autoimmune-prone NOD/ShiLtJ mice were crossed with
DQ8þ mice, lacking endogenous mouse MHC II, to
generate congenic NOD/ShiLtJ DQ8þ mice. Development
of gluten-dependent blistering, associated with IgA deposi-
tion along the dermal–epidermal junction (DEJ), was observed
in 16% of mice, immunized with crude gluten. No blistering
or IgA deposition was seen in NOD/ShiLtJ or DQ8 congenic
mice after gluten sensitization, indicating that both the DQ8
and the NOD/ShiLtJ background are required for blister
formation (Marietta et al., 2004).
To further clarify the relevance of MHC association in
ASBD, we used an established immunization-induced
mouse model for EBA, which reproduces the inflammatory
form of human EBA (Sitaru et al., 2006; Ishii et al., 2011). EBA
is an autoimmune blistering disease, which is characterized
by antibodies to type VII collagen (COL7; Woodley et al.,
1988). Immunization of several inbred mouse strains
identified a significant association of EBA development with
the MHC haplotype H2s. However, this data also pointed
towards a contribution of non-MHC genes to EBA suscept-
ibility. More specifically: (i) MRL/MpJ mice (H2k) developed
experimental EBA; (ii) C57Bl/10.s mice developed a milder
(compared with SJL/J and MRL/MpJ) and mostly transient
disease phenotype (Ludwig et al., 2011); and (iii) C57Bl/6J
mice were susceptible to EBA induction when lacking
expression of the inhibitory Fc gamma RIIB receptor (Sitaru
et al., 2006).
In order to investigate the contribution of non-MHC genes
to EBA susceptibility, in the present study, we generated an
outbred four-way autoimmune-prone intercross mouse line,
originating from MRL/MpJ, BXD2/TyJ, NZM2410/J, and Cast
mice. Using a classical quantitative trait mapping approach
in this outbred family, we identified six loci controlling
susceptibility to murine EBA.
RESULTS
EBA susceptibility of inbred mouse strains
Immunization of MRL/MpJ, NZM2410/J, and BXD2/TyJ mice
with mCOL7C confirmed the previously reported EBA
susceptibility of MRL/MpJ mice (Ludwig et al., 2011). In
contrast, NZM2410/J, BXD2/TyJ, and Cast mice were
resistant to EBA induction (data not shown). Hematoxylin
and eosin studies were in line with the clinical observations,
i.e., subepidermal blistering accompanied by a dermal
leukocyte infiltration was only observed in MRL/MpJ mice.
All strains showed circulating and tissue-bound anti-COL7
IgG (data not shown), supporting the notion that induction of
complement activating antibodies is associated with the
development of clinical EBA (Sitaru et al., 2006; Ludwig
et al., 2011).
Generation of a four-way autoimmune-prone intercross
mouse line
In order to generate a genetically diverse mouse line, EBA-
susceptible (MRL/MpJ) and -resistant mice, and the offspring
of each generation were intercrossed for several generations.
Genetic diversity of this so termed four-way autoimmune-
prone intercross mouse line is reflected by the different
morphological traits, including weight, tail length, or fur
color. Figure 1 reflects these differences in morphology; all
mice shown are from one litter, and all mice present an
individual fur color.
Mice from the four-way autoimmune-prone intercross line are
susceptible to COL7-induced EBA
We next immunized 250 mice from G4 of the four-way
autoimmune-prone intercross mouse line with GST-mCOL7C
emulsified in the adjuvant TiterMax (HiSS Diagnostics
GmbH, Freibrug, Germany). After immunization, mice were
clinically monitored for a period of 12 weeks for the presence
of skin lesions. For analysis, 233 mice were included;
the remaining 17 mice died during the observation period.
The overall incidence of clinically evident EBA was 33%
(Figure 2). On average, onset of disease was observed
7.9±2.8 weeks after immunization. We also observed a
(not statistically significant) trend towards a higher disease
incidence in male (40%) as opposed to female mice (28%).
Most diseased mice presented with mild clinical disease.
However, in 22% of diseased mice, 10% or more of the body
surface area was affected by skin lesions (Figure 2). Disease
extent, expressed as body surface area covered by skin
Parental mice
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Figure 1. Generation of genetic diversity in the four-way autoimmune-prone
intercross line. (a) Schematic diagram of mouse breeding in order to generate
the four-way autoimmune-prone intercross line. Each color represents the
genetic background of the parental inbred mouse lines. By intercrossing each
generation (G) of mice, genomic diversity was obtained. For this study, mice
of the fourth offspring generation (G4) were used, as marked in red.
(b) Female offspring mice from one litter of G6 mice, each showing a different
fur color, thus representing the genetic diversity of this mouse line.
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lesions, ranged from 0.1 to 51.5% with a median of 2%.
Regarding sex, median disease severity was similar in female
and male mice (median 2.6%, range 0.1–51.5%, median
1.3%, range 0.1–28.5%, respectively; P¼ 0.09, rank sum
test). We observed no significant influence of weight or fur
color on EBA susceptibility or severity (data not shown).
Immunization of mice from the same intercross line (G10)
with GST control peptide emulsified in TiterMax did not lead
to the development of skin lesions.
Hematoxylin and eosin–stained sections from a selection
of diseased and clinically healthy mice was in accordance
with the clinical observation, i.e., we detected subepidermal
blisters associated with an inflammatory cell infiltrate in
clinically diseased mice, whereas no histopathological
changes were observed in clinically unaffected animals (data
not shown). Direct immunofluorescence (IF) microscopy
demonstrated IgG deposition in 83% of non-diseased mice,
and in 88% of mice with skin lesions. Deposits of C3 were
detected in 47% of healthy mice, as opposed to 61% in
diseased animals (P¼0.037, w2, Table 1). Detailed analysis of
IgG subclasses (Table 1) showed a predominant IgG2a/c
response in diseased versus healthy mice (Po0.001, Fisher’s
exact test). Furthermore, within diseased mice, analysis of
variance identified decreased IgG1 binding to be significantly
associated with the severity of the disease (P¼ 0.019). No
association with severity could be found for IgG2a/c, IgG2b,
or IgG3. In line with the clinical observation, no IgG or C3
deposits were observed in mice immunized with control
peptide and adjuvant.
Identification of quantitative trait loci in experimental EBA
Susceptibility to immunization-induced EBA was then shown
to be associated with several quantitative trait loci (QTLs).
We analyzed the data regarding the onset of disease
(Figure 3a, Table 2) as well as maximum disease score
(Figure 3b, Table 3). In detail, EBA onset is associated with
four very distinct QTLs on chromosomes 9, 12, 14, and 19.
Chromosome 9 has its peak on rs4135590 (logP 3.8, bp
42796186) and is flanked by the immediate steep drop to
rs13480150 (bp 39531947) and rs13480173 (bp 46336655).
This logP score was not reached by any of the 1,000
permutations (Po0.001). The region of only 7Mbp covers
147 genes. Chromosome 12 has a significant peak at
rs3716095 (logP 3.2, exceeded by 2 of 1,000 permutations,
bp 87934638) at the end of the q arm. It sharply drops
towards the centromere at rs13481561 (bp 83267516) and
towards the terminus at rs6390948 (bp 109917259). This
region covers for 300 genes. Chromosome 14 harbors just a
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Figure 2. Mice of the four-way autoimmune-prone intercross line are susceptible to epidermolysis bullosa acquisita (EBA) induction. (a) Representative
clinical presentations of mice with skin lesions 12 weeks after immunization. (b) Distribution of disease scores (expressed as body surface area covered by
skin lesions) in 233 mice of the four-way autoimmune-prone intercross line 12 weeks after immunization.
Table 1. Induction of complement-fixing antibodies is associated with skin lesions in experimental EBA
Phenotype IgG (total, %) IgG1 (%) IgG2a/c (%) IgG2b (%) IgG3 (%) C3 (%)
EBA 88 86 91 79 46 61
Healthy 83 88 63 77 43 47
Abbreviation: EBA, epidermolysis bullosa acquisita.
Numbers correspond to the percentage of positive IgG/C3 deposition at the dermal–epidermal junction from all 233 mice. Regarding IgG subclasses, IgG2a/c
is binding differently between healthy and affected individuals (Po0.0001, Fisher’s exact test).
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few neighboring markers contributing to the QTL, i.e., steep
drops to either side. The maximum is reached at rs13482216
(logP 2.2, bp 62510281). Its logP value is 2.2 and exceeded
by 1.2% of the permutations, but is still considerably stronger
than peaks located on other chromosomes. With a demanded
drop of 1.5, the region is flanked by markers rs4230248 (bp
31996605) and rs13482265 (79420389), spanning a 38-Mbp
region. Chromosome 19 harbors a highly significant narrow
peak at mCV23069572, flanked by mCV23390953 and the
end of the chromosome (logP 3.3, not exceeded by any
permutation, bp 52876222).
Maximum disease activity (EBA max. score) as a trait
confirmed the identified locus on chromosome 19. This region
also has the strongest logP value of 2.5 for maximum disease
activity, exceeded by only 0.2% of the permutations. The region
is slightly wider than determined for EBA onset, with its peak
again at mCV23069572 (bp 52876222), flanked by rs3687275
(bp 43144678) and the end of the chromosome. A second strong
effect was observed on chromosome 1 at the very beginning of
the p arm from rs3683945 (logP 2.92, only 4 of 1,000
permutations where stronger, bp 3187481) to rs3677683 (bp
27321156). In addition, chromosome 15 harbors a fairly strong
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Figure 3. Identification of quantitative trait loci (QTL) for anti-COL7 IgG production and immunization-induced epidermolysis bullosa acquisita (EBA).
QTL for (a) onset and (b) maximum disease score of immunization-induced EBA. On y axis the log P-value is indicated, while the x axis corresponds
to the mouse genome. *Indicates an association with either onset or maximum score of EBA. Chr, chromosome.
Table 2. QTLs for onset of immunization-induced EBA
Chromosome Flanking–peak–flanking QTL bp Range
9 rs13480150–rs4135590–rs13480173 39531947–46336655
12 rs13481561–rs3716095–rs6390948 83267516–109917259
14 rs13482170–rs13482216–rs3672425 49147300–68964185
19 mCV23390953–mCV23069572–end of chr.19 46090165–end of chr.19
Abbreviations: chr., chromosome; EBA, epidermolysis bullosa acquisita; QTLs, quantitative trait loci.
Table 3. QTLs for maximum disease score of immunization-induced EBA
Chromosome Flanking–peak–flanking QTL bp Range
1 rs3683945–rs3707642–rs3677683 3187481–27321156
15 rs3683495–rs8259436–rs13482687 61034058–85776069
19 rs3687275–mCV23069572–end of chr.19 43144678–end of chr.19
Abbreviations: chr., chromosome; EBA, epidermolysis bullosa acquisita; QTLs, quantitative trait loci.
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peak on rs8259436 (logP 2.15, exceeded by 8 of 1,000
permutations, bp 74680379) that is flanked by rs3683495 (bp
61034058) and rs13482687 (bp 85776069).
Generation of anti-COL7 antibodies is genetically controlled,
but distinct from EBA QTLs
In addition, we also identified QTLs controlling the genera-
tion of anti-COL7-specific IgG, including all murine IgG
subclasses (Table 4). Interestingly, analysis of a possible
common genetic control of specific IgG production and
clinical EBA manifestation did not show an overlap of the
respective QTLs (Table 4).
DISCUSSION
In this study, we identified several QTLs controlling the
susceptibility to experimentally induced EBA. With the
exception of an IL-1b polymorphism in female BP patients
(Chang et al., 2006) and conflicting data on Fc gamma
receptor polymorphisms in BP (Weisenseel et al., 2007;
Guilabert et al., 2010), the contribution on non-MHC genes
has not been reported in patients with ASBD or animal
models for these diseases. The identified QTLs for EBA onset
were found in chromosomes 9, 12, 15, and 19, while QTLs
for the maximal disease score were linked to chromosomes 1,
6, and 19. Interestingly, QTLs for both the traits showed an
overlap on chromosome 19.
From the association data described here, we have
identified a set of possible EBA-associated genes, providing
chromosome assignment. At the moment the data provided
does not allow to link EBA to distinct genes. However, several
genes associated with inflammation and autoimmunity, such
as (i) caspase-7 (Garcia-Lozano et al., 2007; Teixeira et al.,
2008; Akhter et al., 2009), (ii) programmed cell death 4
(Hilliard et al., 2006), (iii) C1q, which initiates complement
activation through the classical pathway (Lachmann and
Hughes-Jones, 1984) and partially contributes to autoanti-
body-induced tissue injury in experimental EBA (Mihai et al.,
2007), and (iv) alpha-mannosidase, which is linked to
chronic activation of the innate immune system (Green
et al., 2007). An activation of innate immune cells is also
required for blister formation in experimental EBA (Chiriac
et al., 2007). However, despite being located within the
identified QTL for EBA, all of the above genes need to be
validated by further intercrossing and tested for functional
relevance; e.g., by use of respective knockout mice. Also of
note, the genetic control of anti-COL7 IgG production did not
overlap with the QTL of clinical EBA manifestation. This may
indicate that the identified QTL predominantly control the
autoantibody-induced tissue injury, rather than the loss of
tolerance.
Interestingly, full-blown disease was detected in 33% of
mice. By intercrossing one EBA-susceptible and three EBA-
resistant mouse strains, we expected a disease incidence of
B25% following a Mendelian distribution of susceptibility
genes from the MRL/MpJ strain. The observed higher
incidence suggests that EBA susceptibility genes are also
located in EBA-resistant mice (BXD2, Cast, and NZM2410).
Previous studies in immunization-induced EBA demon-
strated deposits of C3 in all diseased mice (Sitaru et al., 2006;
Ludwig et al., 2011). Interestingly, in our four-way auto-
immune-prone intercross line, we found disease also in mice
lacking C3 deposition at the DEJ by direct IF microscopy. In
addition, we observed deposition of complement also in
mice with no EBA skin lesions. This suggests that autoanti-
body-induced tissue injury in experimental EBA may be
a stepwise process, which is initiated by deposition
of autoantibodies at the DEJ (Figure 4). Subsequently, a
Table 4. QTLs for generation of anti-COL7 IgG
isotypes in immunization-induced EBA
IgG isotype QTL (flanking–peak–flanking QTL)
Anti-COL7 IgG1 rs13476472–rs3674936–gnf02.076.311
rs13479071–rs13479014–rs3658783
rs3699409–rs3669563–end of chr. 10
Anti-COL7 IgG2a/c gnf01.036.770–rs4137502–rs13475851
rs3684076–rs13481009–rs13481061
rs3655061–gnf13.079.671–rs13481992
Anti-COL7 IgG2b rs3671709–rs3718776–rs6330932
rs13479807–rs3672639–rs4227253
rs13479956–CZECH.8_78291790–rs4227398
rs13482135–rs4230248–rs13482231
Anti-COL7 IgG3 rs13480421–rs6385971–end of chr. 9
rs6309315–rs3686467–gnf19.035.019
Abbreviations: chr., chromosome; EBA, epidermolysis bullosa acquisita;
QTLs, quantitative trait loci.
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Figure 4. Proposed model of autoantibody-induced tissue injury in
experimental epidermolysis bullosa acquisita (EBA). After deposition of
binding of anti-COL7 autoantibodies to the dermal–epidermal junction (DEJ),
Fc-dependent mechanisms lead to the generation of a pro-inflammatory
milieu. This includes the activation of the complement system. On the basis of
the observed induction of EBA in mice without the deposition of C3 at the
DEJ, other mechanisms, e.g., activation of mast cells of resident antigen-
presenting cells (APC) seem to contribute to the generation of the pro-
inflammatory milieu. This will lead to the CD18-dependent (Chiriac et al.,
2007) extravasation of neutrophils. Activation of neutrophils, including
reactive oxygen species (ROS) release (Chiriac et al., 2007) and proteolytic
enzymes (Shimanovich et al., 2004), ultimately leads to blister formation.
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pro-inflammatory milieu is generated in the skin, including
complement activation (Mihai et al., 2007). The pro-
inflammatory milieu promotes recruitment of neutrophils
(Chiriac et al., 2007), leading to Fc receptor–dependent
binding of neutrophils to autoantibodies (Sitaru et al., 2002,
2005; Sesarman et al., 2008). After the activation of
neutrophils, reactive oxygen species (Chiriac et al., 2007)
and proteolytic enzymes (Shimanovich et al., 2004)
mediate blister formation. It is therefore tempting to
speculate that genetic variations in one of these steps, such
as defects in neutrophil activation caused by mutations of
caspase-7, C1q, or a-mannosidase, prevents blister forma-
tion. However, this model, would also allow for a compensa-
tion of one missing factor by others; e.g., the lack of C3
deposition may be compensated by other pro-inflammatory
stimuli induced by autoantibody binding to the DEJ. This
hypothetical model of EBA pathogenesis could explain the
absence of EBA skin lesions despite deposition of comple-
ment at the DEJ, and the induction of skin lesions in mice
lacking C3 deposition at the DEJ. The 12% of mice with
clinical EBA, but negative staining in direct IF microscopy,
we assume, are false negative either due to the kinetics
of IgG deposition at the DEJ (Kasperkiewicz et al., 2010) or
due to false negative DIF readings, which has a sensitivity
of B90–95% in humans (Chan et al., 2003; Pohla-Gubo
et al., 2011).
As the identified QTLs for EBA onset and maximum
disease severity harbor several genes, fine mapping of these
risk alleles is currently pursued by further intercrossing of the
four-way autoimmune-prone mouse line. These studies may
eventually lead to identification of new therapeutic targets for
experimental EBA, which may also have implications for the
human disease and other autoantibody-mediated disorders.
MATERIALS AND METHODS
Animal experiments
Generation of an outbred mouse line. Parental mouse stains
(MRL/MpJ, NZM2410/J, BXD2/TyJ, and Cast) were intercrossed at an
equal strain and sex distribution. Parental origin of generation 1 (G1)
offspring mice was considered when setting up mating for the
generation of G2 mice in order to maintain an equal distribution of
the original strains. This procedure was also followed for intercross-
ing G2 mice. At least 50 breeding pairs were used as parentals for the
next generation of mice. Animals were held under specific pathogen
conditions at a 12-hour light/dark cycle with food and water ad
libitum. All animal experiments were approved by the governmental
administration of the State of Schleswig-Holstein.
Induction of experimental EBA
Induction of EBA has been performed by immunization with an
immunodominant peptide (GST-mCOL7C) within the murine NC1
domain as described (Kasperkiewicz et al., 2010, 2011; Ludwig
et al., 2011). Immunization with GST emulsified in the same
adjuvant was used as control. Every fourth week after immunization,
extent of clinical disease was assessed by evaluating the percentage
of body surface area covered by skin lesions for a total period of
12 weeks. At the end of the experiment, biopsies from lesional and
non-lesional skin, and serum samples were obtained. In total, 6–8
mice, aged 8–10 weeks, from the four parental strains and 250 mice
from the outbred mouse line were immunized with GST-mCOL7C
(G4), and 24 mice (G10) with control protein (GST affinity tag alone
expressed by the use of pGEX-6P-1, GE Healthcare, Frankfurt/Main,
Germany). Parental strains were purchased from Charles River
Laboratories (Sulzfeld, Germany).
Histology and direct IF microscopy
Hematoxylin and eosin staining of skin biopsies (ears) and direct IF
microscopy were performed as described (Kasperkiewicz et al.,
2010). All specimen were obtained at the end of the 12-week
observation period.
ELISA
Detection of circulating COL7 autoantibodies was performed as
described (Kasperkiewicz et al., 2010). In brief, 96-well plates were
coated with His-mCOL7C, followed by incubation with serum from
mice. Bound IgG antibodies were detected using a horseradish
peroxidase-labelled goat anti-mouse IgG (Bethyl Laboratories,
Montgomery, TX) and 3,30,5,50-tetram-ethyl benzidine substrate solution
(Thermo Scientific, Illkirch, France). The color reaction was read at 450nm
using a multilabel counter (Victor 3, Perkin Elmer, Waltham, MA).
Statistical analysis
In total 233 individuals were analyzed, each genotyped by the same
set of 1400 single-nucleotide polymorphisms. The analysis was
performed with the R version of HAPPY (Mott et al., 2000; Durrant
and Mott, 2010) in version 2.3 beta on Debian Linux (Mo¨ller et al.,
2010). The plotting across multiple chromosomes was added locally
and contributed back to the authors of the package. The flanking
regions of QTLs were determined manually by a drop of 1.5 to both
sides to the peak. All QTLs where found significant (Po0.001) by a
point-wise permutation test.
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